EVALUATION OF THE EFFECT OF FAVIPIRAVIR ON MANAGEMENT PATIENT WITH COVID-19

INTERVENTION: Intervention 1: Intervention group: Favipiravir tablet of FUJIFILM company will be given to the patients. The dose is 1600 mg twice daily on first day and days 2–7: 600 mg twice daily. Intervention 2: Control group: Placebo drug (flour tablet) will be given to the patients orally twice daily for 7 days. CONDITION: Coronavirus disease 2019 (COVID19). ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Severity of coronavirus 2019. Timepoint: Before prescription of drug and then every day until 7 days. Method of measurement: pulse oximetry, resspiratory rate, heart rate, CT scan. INCLUSION CRITERIA: All of patients with COVID19 referred to Valiasr and Khansari hospital All of patients in subgroup 3 of hospitalization